chenodeoxycholic acid has been researched along with mgl-3196 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhagani, S; Guaraldi, G; Ingiliz, P; Lemoine, M; Marzolini, C; Maurice, JB; Milic, J; Monteith, K; Morse, CG; Price, JC; Sebastiani, G; Tsochatzis, E | 1 |
| Attia, SL; Mouzaki, M; Softic, S | 1 |
1 review(s) available for chenodeoxycholic acid and mgl-3196
| Article | Year |
|---|---|
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibroblast Growth Factors; Glucosides; Humans; Imidazoles; Isobutyrates; Liraglutide; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Oxazoles; Polyethylene Glycols; Pyridazines; Pyrimidines; Severity of Illness Index; Sulfoxides; Treatment Outcome; Uracil | 2021 |
1 other study(ies) available for chenodeoxycholic acid and mgl-3196
| Article | Year |
|---|---|
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
Topics: Anti-Retroviral Agents; Chalcones; Chenodeoxycholic Acid; Cholic Acids; Clinical Trials, Phase III as Topic; Drug Interactions; HIV Infections; Humans; Imidazoles; Non-alcoholic Fatty Liver Disease; Propionates; Pyridazines; Sulfoxides; Uracil | 2020 |